Cancer Institute A national cancer institute
designated cancer center

RobertĀ W. Carlson

Publication Details

  • A PHASE-II TRIAL OF CARBETIMER FOR THE TREATMENT OF COLORECTAL-CANCER - A TRIAL OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS AUDEH, M. W., Jacobs, C. D., Davis, T. E., Carlson, R. W. 1990; 13 (4): 324-326

    Abstract:

    Carbetimer (carboxyimamidate) was administered at a dose of 6,500 mg/m2/day intravenously for 5 consecutive days to 14 patients with measurable metastatic or recurrent colorectal cancer in a single institution phase II study of the Northern California Oncology Group. A total of 38 cycles of therapy were administered; nine patients completed at least three cycles of treatment. No partial or complete responses were observed. One patient did have a greater than 50% response in the liver while developing new retroperitoneal lymphadenopathy and is considered a nonresponder. Carbetimer was well tolerated with elevations of calcium from 10.2 to 12.5 mg/dl in nine patients, prolongation of prothrombin time and partial thromboplastin time in 14 patients, proteinuria in 10 patients, dizziness in six patients, nausea in two patients, and venous pain during infusion in three patients. Myelosuppression was not observed. Carbetimer at this dose and schedule is inactive in the treatment of colorectal cancer.

    View details for Web of Science ID A1990DT05600012

    View details for PubMedID 2198795

Stanford Medicine Resources:

Footer Links: